RecruitingMigraine
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Eligible age
0+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Sponsor: Pfizer
You may qualify if…
- ✓ Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
- ✓ Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy
You may not qualify if…
- ✕ Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy
Where it's recruiting
North Carolina
Wilmington
Source: ClinicalTrials.gov · NCT05046613 · last updated 2026-05-05